Anika Therapeutics (ANIK) Stock Rating Lowered by BidaskClub

Anika Therapeutics (NASDAQ:ANIK) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Friday.

ANIK has been the subject of several other reports. Zacks Investment Research cut Anika Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, February 26th. Barrington Research restated a “buy” rating and set a $57.00 target price on shares of Anika Therapeutics in a research report on Thursday, December 28th. Sidoti started coverage on Anika Therapeutics in a research report on Friday, January 26th. They set a “buy” rating for the company. ValuEngine cut Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, April 12th. Finally, First Analysis upgraded Anika Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $45.00 to $68.00 in a report on Wednesday, January 24th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $62.50.

Anika Therapeutics stock opened at $45.13 on Friday. Anika Therapeutics has a 52 week low of $42.51 and a 52 week high of $69.81. The stock has a market cap of $671.35, a P/E ratio of 23.03, a price-to-earnings-growth ratio of 2.90 and a beta of 1.73.



Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, February 21st. The biotechnology company reported $0.38 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.41 by ($0.03). Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The business had revenue of $29.39 million for the quarter, compared to analysts’ expectations of $29.85 million. During the same quarter in the previous year, the firm earned $0.54 earnings per share. Anika Therapeutics’s quarterly revenue was up 2.3% compared to the same quarter last year. equities research analysts predict that Anika Therapeutics will post 1.57 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of ANIK. SG Americas Securities LLC purchased a new position in shares of Anika Therapeutics in the 3rd quarter worth about $118,000. JPMorgan Chase & Co. boosted its holdings in shares of Anika Therapeutics by 2,781.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,859 shares of the biotechnology company’s stock worth $982,000 after purchasing an additional 16,274 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Anika Therapeutics by 25.0% in the 3rd quarter. Wells Fargo & Company MN now owns 209,928 shares of the biotechnology company’s stock worth $12,176,000 after purchasing an additional 42,015 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of Anika Therapeutics by 2.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 895,600 shares of the biotechnology company’s stock worth $51,945,000 after purchasing an additional 17,594 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. boosted its holdings in shares of Anika Therapeutics by 415.7% in the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,194 shares of the biotechnology company’s stock worth $359,000 after purchasing an additional 4,993 shares in the last quarter. Hedge funds and other institutional investors own 84.10% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/04/22/anika-therapeutics-anik-stock-rating-lowered-by-bidaskclub.html.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply